January 08, 2024

| | |
|---|---|
| To<br>Listing Department,<br>**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**<br>Exchange Plaza,<br>Bandra Kurla Complex, Bandra (E),<br>**MUMBAI -400 051**<br><br>**Company Code No. AUROPHARMA** | To<br>The Corporate Relations Department<br>**BSE LIMITED**<br>Phiroze Jeejeebhoy Towers,<br>25th floor, Dalal Street,<br>**MUMBAI -400 001**<br><br>**Company Code No. 524804** |

Dear Sir/Madam,

**Sub: Classification of US FDA Inspection at our Unit VI-B – Reg.,**

**Ref: Our letter dated September 30, 2023**

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The U.S. Food and Drug Administration (FDA) had conducted an inspection at the Unit VI-B, a Formulation manufacturing facility of the Company, situated at Chitkul Village, Patancheru Mandal, Sangareddy District, Telangana, from September 22 to September 29, 2023.

The Unit has now received Establishment Inspection Report classifying the facility as "Voluntary Action Indicated" ("VAI").

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

Digitally signed by BADDIGAM ADI REDDY
Date: 2024.01.08 19:02:11 +05'30'

B. Adi Reddy
Company Secretary